Satralizumab 120 mg ( DrugBank: Satralizumab )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 13 | 多発性硬化症／視神経脊髄炎 | 1 |
13. 多発性硬化症／視神経脊髄炎
臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05269667 (ClinicalTrials.gov) | August 2, 2022 | 15/2/2022 | A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention | SAkuraBonsai: Clinical, Imaging And Biomarker Open-Label Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention | Neuromyelitis Optica Spectrum Disorder;NMOSD | Drug: Satralizumab 120 mg | Hoffmann-La Roche | Chugai Pharmaceutical Co. | Recruiting | 18 Years | 74 Years | All | 100 | Phase 4 | United States;France;Italy;Japan;Korea, Republic of;Turkey;Canada;Germany;India |